Ribosomal RNA on the surfaces of nonleukemic mouse ascites tumor cells.
RNAs on the cell surfaces of two nonleukemic and two leukemic strains of mouse ascites tumor cells were studied by fractionating the RNAs released from the cell surface by gentle pronase treatment after sucrose density gradient centrifugation, by indirect membrane immunofluorescence that used anti-RNA antibody and by cell electrophoresis. RNA was extracted from the cell supernatants of Ehrlich ascites tumor and sarcoma 180 cells (nonleukemic) that had been treated or not treated with pronase (1 microgram/ml, 37 degrees C, 20 min) followed by sucrose density gradient centrifugation. It was clearly demonstrated that the amounts of ribosomal RNA (18S and 28S) released after pronase treatment were approximately 80% greater than that of nonpronase-treated cells. Ehrlich ascites tumor cells that had been treated with actinomycin D (100 micrograms/kg body weight of mouse, 16 h) in vivo released an amount of ribosomal RNA after pronase treatment only 20% greater than the value for untreated cells. Actinomycin D treatment greatly reduced both the cell surface negative charge and the cell surface immunofluorescence when rabbit anti-RNA antibody was used. Under the same experimental conditions with actinomycin D, only ribosomal RNA synthesis showed preferential inhibition, not the syntheses of poly A-containing messenger RNA, 4S or other small-size RNAs. In contrast, L1210 and C1498 cells (leukemic) showed no change in the amounts of ribosomal RNA released after pronase treatment. L1210 cells also showed no change in the surface negative charge after being treated with actinomycin D.(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000032:analysis / Q000378:metabolism* / Q000473:pathology; D002460:Cell Line; D002462:Cell Membrane / Q000032:analysis*; D002465:Cell Movement; D002499:Centrifugation, Density Gradient; D003609:Dactinomycin / Q000008:administration & dosage / Q000494:pharmacology; D004586:Electrophoresis; D005455:Fluorescent Antibody Technique; D007267:Injections; D007939:Leukemia L1210 / Q000473:pathology; D007942:Leukemia, Experimental / Q000473:pathology; D007951:Leukemia, Myeloid / Q000473:pathology; D051379:Mice; D011402:Pronase / Q000494:pharmacology; D012335:RNA, Ribosomal / Q000032:analysis* / Q000378:metabolism
D012335:RNA, Ribosomal; D003609:Dactinomycin; D011402:Pronase